NCT06393751 2025-06-03
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
Clinical Trials
1 trialsPhase 1/2 × Platinum-Refractory Fallopian Tube Carcinoma × Magnetic Resonance Spectroscopy × Clear all